| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics |
Department of Therapeutic Radiology-Radiation Oncology, University of Minnesota Medical School, Minneapolis, Minnesota 55455 [R. J. G., B. W. W., H. P., C. W. S.], and Sugen, Inc, South San Francisco, California 94080 [R. W., J. M. C.]
 |
ABSTRACT |
|---|
 Top ABSTRACT INTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
|
INTRODUCTION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
It has been repeatedly demonstrated that antiangiogenic treatment is potentially useful to halt tumor growth. Among a number of emerging strategies that aim at nullifying tumor angiogenesis, blocking the interaction of growth factors with their receptors has been demonstrated to be potentially useful (5 , 6 , 14) . For example, significant antitumor effects have been observed with the use of antibodies raised against VEGFRs (5 , 14) . Recent studies have also demonstrated that the inhibition of the kinase activity of VEGFRs suppresses tumor growth by inhibiting angiogenesis. SU5416, 3-[(2,4-dimethylpyrrol-5-yl) methylidenyl]-indolin-2-one, is a synthetic small molecule designed to inhibit VEGFR-2 (Flk-1/KDR) tyrosine kinase activity, and it causes marked growth inhibition in a variety of experimental tumors (15, 16, 17, 18, 19, 20) . Phase III clinical trials to evaluate this drug are presently in progress (21) .
In light of the important role of VEGF, FGF, and PDGF and their receptors in tumor angiogenesis, it is reasonable to expect that simultaneously antagonizing the VEGF, FGF, and PDGF signaling pathways may be more effective than antagonizing VEGF signal transduction alone. SU6668, (Z)-3-[2,4-dimethyl-5-(2-oxo-1,2-dihydro-3-ylidenemethyl)-1H-pyrrol-3-yl]-propionic acid, is a multipurpose small synthetic molecule designed to inhibit the kinase activity of FGF and PDGF receptors as well as VEGFRs (22) . The antiangiogenic and antitumor effects of SU6668 have recently been demonstrated in a variety of experimental tumors (20 , 22, 23) .
Importantly, various antiangiogenic agents have been demonstrated to enhance the response of murine tumors to chemotherapy or radiotherapy. Although the mechanism is not yet completely understood, these studies may represent what is becoming a paradigm shift in the type of adjuvant treatment to be used with traditional chemotherapy or radiotherapy (14 , 24, 25, 26, 27, 28) . In this connection, it has been reported that the inhibition of VEGFR tyrosine kinase activity using SU5416 markedly enhanced the radioresponse of experimental tumors (19) . We have investigated the effect of SU6668, which inhibits VEGF, FGF, and PDGF receptor kinases, on the response of tumors to radiotherapy in the present study. To our knowledge this is one of the first studies to elucidate the effects of simultaneous inhibition of multiple angiogenic growth factors on the response of tumors to ionizing radiation. In addition, we have for the first time quantified the effect of SU6668 on tumor blood perfusion to better understand the antitumor effects of this intriguing compound alone and as an adjuvant therapy.
|
MATERIALS AND METHODS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
FSaII Tumor.
This fibrosarcoma of C3H mice (Jackson Laboratories) was originally obtained from the laboratory of Dr. Herman Suit (Massachusetts General Hospital, Boston, MA). Stock cells are stored in liquid nitrogen and new cultures are established every 2–3 months. The SCK and FSaII tumor cells grow well in RPMI 1640 supplemented with 10% calf serum.
CFPAC Human Pancreatic Carcinoma.
This human pancreatic carcinoma (American Type Culture Collection, Manassas, VA) is grown in Balb/cAnNCrl-nuBr nude mice (Charles River Labs, Wilmington, MA). Cells stored in liquid nitrogen are grown in Iscove’s modified Dulbecco’s medium with 10% FCS (Life Technologies, Inc.).
Tumor Induction
The SCK and FSaII tumor cells in exponential growth phase in culture were harvested using 0.25% trypsin and were washed and counted. About 2 x 105 cells in 0.05 ml of serum-free medium were injected s.c. into the hind thigh of male A/J mice for SCK tumors and female C3H mice for FSaII tumors. The SCK tumors and FSaII tumors grow to 250 mm3 in about 8 days and 12 days, respectively. The CFPAC tumor cells were harvested using a 0.05% trypsin-EDTA mixture, washed, suspended in Dulbecco’s PBS, and counted. About 1 x 106 cells in 0.05 ml of PBS were injected s.c. into the hind thigh of female nude mice. The CFPAC tumors grew to 250 mm3 in 
21 days. The tumor size was determined using a caliper, and the tumor volume was calculated using the formula a2b/2, where a and b are the shorter and longer diameters of the tumor, respectively.
Drug Treatments
Starting on the day when the tumors had grown to the desired volume, depending on the purpose of the experiment, the tumor-bearing mice received i.p. once-a-day injections of 100 mg/kg SU6668 (Sugen Inc., South San Francisco, CA) dissolved in 0.05 ml of DMSO. Control animals received injections of the same volume of DMSO.
Irradiation of Tumors
The A/J mice bearing SCK tumors were treated with 100 mg/kg SU6668 once a day for two days. Two h after the second SU6668 treatment, the host mice were anesthetized with an i.p. injection of a mixture of 100 mg/kg ketamine and 10 mg/kg xylazine. About 15 min later, the mice were covered with a 4 mm thick lead shield and the tumor-bearing legs were gently extended into the radiation field and exposed to X-rays at a dose rate of 1.4 Gy/min. A Philips 250 kV orthovoltage machine (Philips Medical Systems, Brookfield, WI) was used for the irradiation.
Blood Perfusion Determination
The blood perfusion in tumors and several normal tissues was measured with the 86RbCl uptake method (29)
. The mice were anesthetized as described above, 5 µCi of 86RbCl in 0.1 ml of PBS was injected through the lateral tail vein, and the mice were killed 60 s later by cervical dislocation. The tissues were removed, weighed, and the radioactivity was counted with a well-type gamma counter (1282 Compugamma; Pharmacia LKB Wallac, Turku, Finland). From the radioactivity in the tissue sample and that in the reference, the percentage of injected 86RbCl per gram of tissue was calculated.
Statistical Analysis
Data sets were analyzed using a commercially available software package (InStat 2.03, Graphpad Software, Inc.). A two-tailed Student’s t test was used to determine the validity of the differences between control and treatment data sets. A P of 0.05 or less was considered significant.
|
RESULTS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
shows that daily i.p. injection of SU6668 at 100 mg/kg significantly suppressed the growth of CFPAC tumors, FSaII tumors, and SCK tumors. The treatment of CFPAC tumors with SU6668 was begun when the tumor volume reached 250–300 mm3 . The volume doubling time of control CFPAC tumors was 8.9 ± 0.9 days, whereas daily treatment with SU6668 increased the tumor volume doubling time to 18.8 ± 0.7 days (P < 0.0001). Control FSaII tumors that averaged 250 mm3 grew to 1000 mm3, a 4-fold increase, in 9.4 ± 0.7 days, whereas the volume of tumors treated with SU6668 increased four times in 13.4 ± 0.8 days (P < 0.006). The growth of SCK tumors was also significantly suppressed by SU6668 treatment. To reveal whether the efficacy of SU6668 on tumor growth depends on the tumor size at the start of treatment, we began treating SCK-bearing host mice with SU6668 when the tumor volume reached either 125 mm3 or 250 mm3. SU6668 treatment was effective in suppressing the growth of both 125 mm3 and 250 mm3 tumors. The large and small control tumors grew 4-fold in volume in 6.4 ± 0.3 and 5.0 ± 0.8 days, respectively, whereas large and small tumors treated with SU6668 grew 4-fold in volume in 9.5 ± 0.3 days and 7.9 ± 1.5 days, respectively (P 
0.007). The difference between the growth delay of large (3.1 days) and small (2.9 days) tumors caused by SU6668 treatment was not statistically significant.
|
shows the effect of daily treatment of mice bearing SCK tumors with SU6668 or vehicle (DMSO) on the survival time of the host mice. The treatment was started when the tumors reached 125 mm3 (4–5 days after tumor cell inoculation) and the day of death represents the number of days after treatments were started. The control mice treated with only the vehicle started to die on day 4, and all of the control animals died by day 12, when the primary tumor volume had reached an average of 1575 ± 197 mm3. On the other hand, the mice treated with SU6668 began to die on day 10, and some tumor-bearing mice survived until day 18, when the average primary tumor volume was 1878 ± 105 mm3. The median survival time of host mice treated with only the vehicle was 8 days, whereas that of mice treated with SU6668 was 14 days after the start of treatment.
|
. The 86Rb uptake in control SCK tumors was 2.1 ± 0.2% of the total injected radioactivity per gram. As shown in Fig. 3A
, when host mice received an injection of a single dose of 100 mg/kg of SU6668, the 86Rb uptake in SCK tumors decreased to about one-half of that in control mice within the 1st hour after drug administration (P < 0.008). The perfusion recovered to control level by 8 h and increased to about 40% above the corresponding control value by 24 h after injection (P = 0.03). At 2 h after a second dose of 100 mg/kg SU6668, given 24 h after the first dose, the blood perfusion again declined to 75% of the control value (P = 0.05). The perfusion in the skin, muscle, and kidney of A/J mice was measured concomitantly with the tumor blood perfusion. In contrast to the effects of SU6668 on tumor perfusion, there was no significant difference in normal tissue perfusion found between control and drug-treated mice except for the kidney perfusion at 1 h after SU6668 injection, which decreased to 60% of control level and recovered completely by 4 h (data not shown).
|
shows the effect of daily administrations of SU6668 on tumor blood perfusion determined by measuring 86Rb uptake in the FSaII and CFPAC tumors that were used to study the effect of SU6668 on tumor growth (shown in Fig. 1
). The 86Rb uptake in the control CFPAC and FSaII tumors was 2.8 ± 0.3%/g and 1.3 ± 0.3%/g, respectively. At 24 h after the last of 17 daily injections with SU6668, the 86Rb uptake in CFPAC and FSaII tumors was reduced to 1.9 ± 0.3%/g and 0.5 ± 0.1%/g, respectively (P 0.05). The 86Rb uptake in control SCK tumors was 2.1 ± 0.2%/g, as stated above, but 24 h after 7 daily injections of 100 mg/kg SU6668, the 86Rb uptake was reduced to 1.4 ± 0.3%/g (P = 0.01).
Enhancement of Tumor Radiation Response.
After SCK tumors grew to about 125 mm3, we began daily treatment of the host mice with 100 mg/kg of SU6668. Tumors were irradiated with 15 Gy of X-rays 2 h after the second drug treatment, and daily treatment of host mice with SU6668 was continued after tumor irradiation until the end of the experiment. Fig. 4
shows that the suppression of tumor growth caused by daily 100 mg/kg SU6668 was slightly greater than that caused by 15 Gy of radiation, and the combination of SU6668 treatment and radiation was far more effective than either treatment alone. In Table 1
the number of days required for the tumors to grow four times in volume after various treatments are compared. The tumor-growth delay caused by daily 100 mg/kg SU6668 treatment in combination with 15-Gy irradiation was 15.3 ± 1.6 days which was roughly triple that caused by either of these treatments alone (P 0.0003). There was also a synergistic effect of SU6668 and tumor irradiation on animal survival. The mice in the X-irradiation-alone group and SU6668-treatment-alone group began to die on day 6 and 10, respectively, whereas none of the host mice that received the combined treatments died before day 26 (data not shown).
|
|
|
DISCUSSION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
was apparently related to the marked decline in tumor blood perfusion caused by SU6668 (Fig. 3)
. Microscopic observation of vascular density in histological preparations of tumors and changes in vascular patterns in small tumors grown in window chambers are commonly used as a measure of antiangiogenesis. Although these methods are useful to investigate morphological and structural changes in blood vessels, we believe that measuring actual tumor blood perfusion, an important and novel part of the present study, is an invaluable indicator of the action of antiangiogenic agents on existing tumor vasculature.
A question that remains is what amount of the reduction of tumor blood perfusion after multiple daily treatments with SU6668 (Fig. 3B)
was attributable to the inhibition of new blood vessel formation as opposed to damage to existing tumor blood vessels. It has been reported that VEGF, FGF, and PDGF may be required not only for angiogenesis but also for survival of existing endothelial cells (20)
. Therefore, it is probable that the marked reduction of tumor blood flow caused by extended treatment with SU6668 in the present study was caused, in part, by damage of existing tumor vasculature. In this connection, the early response of tumor microvasculature to SU6668 treatment has been recently reported (30)
. Here, SU6668 induced apoptosis in tumor vessels within 6–12 h after drug administration. Moreover, SU6668 treatment resulted in a decrease in tumor mitotic index and dramatically reduced the functional microvessel density in the tumor. These data suggest that the antitumor action of SU6668 is, at least in part, dependent on a significant degree of damage to existing vessels.
Interestingly, although the tumor blood perfusion decreased in the 1st hour after a single i.p. injection of SU6668, it increased by 24 h after the drug administration (Fig. 3A)
. This observation may be related to the findings of Laird et al. that when the tumor endothelium was undergoing breakdown several hours after SU6668 treatment, VEGF transcript levels in RNA isolated from the tumor were elevated 2- to 3-fold and then returned to near normal levels by 24 h (30)
. One interpretation of these data are that the rapid vessel perturbation and the accompanying reduction in tumor perfusion caused by SU6668 resulted in hypoxic stress in the tumor tissue leading to induction of VEGF transcription. VEGF is known to induce nitric oxide production leading to increases in vascular permeability and vasodilation (31)
, which may explain why blood perfusion was transiently elevated after the single dose of SU6668. Ultimately, repeated administration of SU6668 may render many vessels nonfunctional because of a massive loss of endothelial cells. Clearly, the complete mechanism of the dynamic changes in tumor perfusion after single or multiple injections of SU6668 needs further elucidation.
The ability of SU6668 to significantly prolong the survival time of tumor-bearing host mice (Fig. 2)
is potentially important and echoes the results of other recent studies (20
, 23)
. In our studies, we treated A/J mice bearing SCK tumors, which normally metastasize to the lung, with SU6668 at 100 mg/kg/day beginning when the tumors were about 125 mm3 in size. An example of lung preparations of tumor-bearing A/J mice treated for 7 days with either DMSO or 100 mg/kg SU6668 is shown in Fig. 5
. In a preliminary histological study, we observed that in lung sections from DMSO-treated tumor-bearing mice, there were 9.8 ± 3.7 metastatic loci/section, whereas only 2.3 ± 0.3 metastatic loci/section were observed in the lungs of tumor-bearing mice treated daily with SU6668. In addition, the size of the metastases in the lungs of mice treated with SU6668 was noticeably smaller than that in DMSO-treated control mice. The significant decline in the number and size of metastatic nodules in the lung seems to reflect the prolonged survival time caused by SU6668. Our future studies aim at determining the mechanism of the survival benefit afforded to tumor-bearing mice by SU6668 treatment.
|
. Therefore, the increase in radiation response of the tumors by exposure to SU6668 did not appear to have resulted from an increase in tumor oxygenation via an increase in tumor blood perfusion. We cannot rule out, however, the possibility that SU6668 alters the oxygen consumption rate in the tumor endothelium, the tumor cells, or both. Although significant, our results lean toward an additive rather than an interactive effect of the combination of SU6668 and radiation. We are currently working to understand the optimal combined treatment scheme to produce a greater-than-additive antitumor response. A recent study has demonstrated that SU5416, an inhibitor of VEGF receptor kinase, increased the radiation-induced apoptosis in endothelial cells (19)
. It has also been reported that SU6668 caused apoptosis in endothelial cells in vivo (23)
. Taken together, these data suggest that enhancement of tumor response to radiation by SU6668 may occur most readily by increasing the radiosensitivity of tumor blood vessels. In conclusion, this study indicates that the multipotent angiogenesis inhibitor SU6668 is effective in perturbing existing tumor vascular function and further uncovers the mechanism(s) by which growth-factor inhibition alters tumor growth. Our data shows that SU6668, currently in Phase I clinical trials (21) , has potential in combating tumor progression and may be particularly effective as an adjuvant to radiotherapy of human tumors.
|
ACKNOWLEDGMENTS |
|---|
|
FOOTNOTES |
|---|
1 Supported by NIH Grant CA13353. 
2 To whom requests for reprints should be addressed, at Department of Therapeutic Radiology-Radiation Oncology, 420 Delaware Street SE, MMC 494, University of Minnesota Medical School, Minneapolis, MN 55455.
3 The abbreviations used are: VEGF, vascular endothelial growth factor; FGF, fibroblast growth factor; PDGF, platelet-derived growth factor; VEGFR, VEGF receptor.
4 R. Wild et al., unpublished observations.
Received 10/23/01. Accepted 1/16/02.
|
REFERENCES |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
and ß subtypes. Growth Factors, 16: 291-216, 1999.
This article has been cited by other articles:
|
|
 |
|
  T. Iwasa, I. Okamoto, M. Suzuki, E. Hatashita, Y. Yamada, M. Fukuoka, K. Ono, and K. Nakagawa Inhibition of Insulin-Like Growth Factor 1 Receptor by CP-751,871 Radiosensitizes Non-Small Cell Lung Cancer Cells Clin. Cancer Res., August 15, 2009; 15(16): 5117 - 5125. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. W. SIEMANN, C. M. NORRIS, A. RYAN, and W. SHI Impact of Tumor Cell VEGF Expression on the In Vivo Efficacy of Vandetanib (ZACTIMATM; ZD6474) Anticancer Res, June 1, 2009; 29(6): 1987 - 1992. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Ma and D. J. Waxman Combination of antiangiogenesis with chemotherapy for more effective cancer treatment Mol. Cancer Ther., December 1, 2008; 7(12): 3670 - 3684. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A C Browning, H S Dua, and W M Amoaku The effects of growth factors on the proliferation and in vitro angiogenesis of human macular inner choroidal endothelial cells Br J Ophthalmol, July 1, 2008; 92(7): 1003 - 1008. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Timke, H. Zieher, A. Roth, K. Hauser, K. E. Lipson, K. J. Weber, J. Debus, A. Abdollahi, and P. E. Huber Combination of Vascular Endothelial Growth Factor Receptor/Platelet-Derived Growth Factor Receptor Inhibition Markedly Improves Radiation Tumor Therapy Clin. Cancer Res., April 1, 2008; 14(7): 2210 - 2219. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ekman, M. Bergqvist, C.-H. Heldin, and J. Lennartsson Activation of Growth Factor Receptors in Esophageal Cancer Implications for Therapy Oncologist, October 1, 2007; 12(10): 1165 - 1177. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Sennino, B. L. Falcon, D. McCauley, T. Le, T. McCauley, J. C. Kurz, A. Haskell, D. M. Epstein, and D. M. McDonald Sequential Loss of Tumor Vessel Pericytes and Endothelial Cells after Inhibition of Platelet-Derived Growth Factor B by Selective Aptamer AX102 Cancer Res., August 1, 2007; 67(15): 7358 - 7367. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. P.M. Dings, M. Loren, H. Heun, E. McNiel, A. W. Griffioen, K. H. Mayo, and R. J. Griffin Scheduling of Radiation with Angiogenesis Inhibitors Anginex and Avastin Improves Therapeutic Outcome via Vessel Normalization Clin. Cancer Res., June 1, 2007; 13(11): 3395 - 3402. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Horsman and D. W. Siemann Pathophysiologic Effects of Vascular-Targeting Agents and the Implications for Combination with Conventional Therapies Cancer Res., December 15, 2006; 66(24): 11520 - 11539. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Naumova, P. Ubezio, A. Garofalo, P. Borsotti, L. Cassis, E. Riccardi, E. Scanziani, S. A. Eccles, M. R. Bani, and R. Giavazzi The Vascular Targeting Property of Paclitaxel Is Enhanced by SU6668, a Receptor Tyrosine Kinase Inhibitor, Causing Apoptosis of Endothelial Cells and Inhibition of Angiogenesis. Clin. Cancer Res., March 15, 2006; 12(6): 1839 - 1849. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. N. Cheema, T. Hong, N. Nili, A. Segev, J. G. Moffat, K. E. Lipson, A. R. Howlett, D. W. Holdsworth, M. J. Cole, B. Qiang, et al. Adventitial Microvessel Formation After Coronary Stenting and the Effects of SU11218, a Tyrosine Kinase Inhibitor J. Am. Coll. Cardiol., March 7, 2006; 47(5): 1067 - 1075. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. R. Pradeep, E. S. Sunila, and G. Kuttan Expression of Vascular Endothelial Growth Factor (VEGF) and VEGF Receptors in Tumor Angiogenesis and Malignancies Integr Cancer Ther, December 1, 2005; 4(4): 315 - 321. [Abstract] [PDF]
|
|
|
|
|
|
K. Godl, O. J. Gruss, J. Eickhoff, J. Wissing, S. Blencke, M. Weber, H. Degen, D. Brehmer, L. Orfi, Z. Horvath, et al. Proteomic Characterization of the Angiogenesis Inhibitor SU6668 Reveals Multiple Impacts on Cellular Kinase Signaling Cancer Res., August 1, 2005; 65(15): 6919 - 6926. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Hayashida, M. Ueda, K. Aiura, H. Tada, M. Onizuka, M. Seno, H. Yamada, and M. Kitajima Anti-angiogenic effect of an insertional fusion protein of human basic fibroblast growth factor and ribonuclease-1 Protein Eng. Des. Sel., July 1, 2005; 18(7): 321 - 327. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Zips, W. Eicheler, P. Geyer, F. Hessel, A. Dorfler, H. D. Thames, M. Haberey, and M. Baumann Enhanced Susceptibility of Irradiated Tumor Vessels to Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibition Cancer Res., June 15, 2005; 65(12): 5374 - 5379. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. E. Huber, M. Bischof, J. Jenne, S. Heiland, P. Peschke, R. Saffrich, H.-J. Grone, J. Debus, K. E. Lipson, and A. Abdollahi Trimodal Cancer Treatment: Beneficial Effects of Combined Antiangiogenesis, Radiation, and Chemotherapy Cancer Res., May 1, 2005; 65(9): 3643 - 3655. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B Kwabi-Addo, M Ozen, and M Ittmann The role of fibroblast growth factors and their receptors in prostate cancer Endocr. Relat. Cancer, December 1, 2004; 11(4): 709 - 724. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. M. Fenton, S. F. Paoni, and I. Ding Pathophysiological Effects of Vascular Endothelial Growth Factor Receptor-2-Blocking Antibody plus Fractionated Radiotherapy on Murine Mammary Tumors Cancer Res., August 15, 2004; 64(16): 5712 - 5719. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Kulke, R. D. Odze, J. D. Mueller, H. Wang, M. Redston, and M. M. Bertagnolli Prognostic significance of vascular endothelial growth factor and cyclooxygenase 2 expression in patients receiving preoperative chemoradiation for esophageal cancer J. Thorac. Cardiovasc. Surg., June 1, 2004; 127(6): 1579 - 1586. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Marzola, A. Degrassi, L. Calderan, P. Farace, C. Crescimanno, E. Nicolato, A. Giusti, E. Pesenti, A. Terron, A. Sbarbati, et al. In Vivo Assessment of Antiangiogenic Activity of SU6668 in an Experimental Colon Carcinoma Model Clin. Cancer Res., January 15, 2004; 10(2): 739 - 750. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Choy and L. Milas Enhancing Radiotherapy With Cyclooxygenase-2 Enzyme Inhibitors: A Rational Advance? J Natl Cancer Inst, October 1, 2003; 95(19): 1440 - 1452. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. K. Rofstad, K. Henriksen, K. Galappathi, and B. Mathiesen Antiangiogenic Treatment with Thrombospondin-1 Enhances Primary Tumor Radiation Response and Prevents Growth of Dormant Pulmonary Micrometastases after Curative Radiation Therapy in Human Melanoma Xenografts Cancer Res., July 15, 2003; 63(14): 4055 - 4061. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Davies, J. Salter, M. Hills, L.-A. Martin, N. Sacks, and M. Dowsett Correlation between Cyclooxygenase-2 Expression and Angiogenesis in Human Breast Cancer Clin. Cancer Res., July 1, 2003; 9(7): 2651 - 2656. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Wachsberger, R. Burd, and A. P. Dicker Tumor Response to Ionizing Radiation Combined with Antiangiogenesis or Vascular Targeting Agents: Exploring Mechanisms of Interaction Clin. Cancer Res., June 1, 2003; 9(6): 1957 - 1971. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Sonveaux, A. Brouet, X. Havaux, V. Gregoire, C. Dessy, J.-L. Balligand, and O. Feron Irradiation-induced Angiogenesis through the Up-Regulation of the Nitric Oxide Pathway: Implications for Tumor Radiotherapy Cancer Res., March 1, 2003; 63(5): 1012 - 1019. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Facchiano, K. Russo, A. M. Facchiano, F. De Marchis, F. Facchiano, D. Ribatti, M. S. Aguzzi, and M. C. Capogrossi Identification of a Novel Domain of Fibroblast Growth Factor 2 Controlling Its Angiogenic Properties J. Biol. Chem., February 28, 2003; 278(10): 8751 - 8760. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
